Antibiotic Discovery Hurdles: Could Data Sharing, Research Hub Solve Problem?
This article was originally published in The Pink Sheet Daily
Executive Summary
With input from industry, Pew Charitable Trusts proposes formation of entity dedicated to basic research; first step is finding someone to fund the estimated $200m cost for five-year initiative.
You may also be interested in...
Cempra's Solithromycin On Track To Enter Generic, But Resistant, CABP Market
FDA schedules November advisory committee for Cempra's first-in-class antibiotic for community-acquired bacterial pneumonia.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.